- Home
- MCS vs PRAX Comparison
MCS vs PRAX Comparison
Compare MCS & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCS
- PRAX
- Stock Information
- Founded
- MCS 1935
- PRAX 2015
- Country
- MCS United States
- PRAX United States
- Employees
- MCS N/A
- PRAX N/A
- Industry
- MCS Movies/Entertainment
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- MCS Consumer Discretionary
- PRAX Health Care
- Exchange
- MCS Nasdaq
- PRAX Nasdaq
- Market Cap
- MCS 537.6M
- PRAX 599.7M
- IPO Year
- MCS N/A
- PRAX 2020
- Fundamental
- Price
- MCS $17.21
- PRAX $42.34
- Analyst Decision
- MCS Strong Buy
- PRAX Strong Buy
- Analyst Count
- MCS 4
- PRAX 11
- Target Price
- MCS $23.75
- PRAX $114.73
- AVG Volume (30 Days)
- MCS 174.4K
- PRAX 279.7K
- Earning Date
- MCS 07-31-2025
- PRAX 08-12-2025
- Dividend Yield
- MCS 1.63%
- PRAX N/A
- EPS Growth
- MCS N/A
- PRAX N/A
- EPS
- MCS N/A
- PRAX N/A
- Revenue
- MCS $704,626,000.00
- PRAX $8,122,000.00
- Revenue This Year
- MCS $13.05
- PRAX N/A
- Revenue Next Year
- MCS $4.23
- PRAX $6,358.50
- P/E Ratio
- MCS N/A
- PRAX N/A
- Revenue Growth
- MCS 3.81
- PRAX 270.02
- 52 Week Low
- MCS $10.45
- PRAX $26.70
- 52 Week High
- MCS $23.16
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- MCS 48.09
- PRAX 54.36
- Support Level
- MCS $17.02
- PRAX $41.64
- Resistance Level
- MCS $17.47
- PRAX $44.99
- Average True Range (ATR)
- MCS 0.38
- PRAX 2.55
- MACD
- MCS -0.08
- PRAX -0.11
- Stochastic Oscillator
- MCS 16.74
- PRAX 51.07
About MCS Marcus Corporation (The)
Marcus Corp is engaged in two business segments, which are movie theatres and Hotels and Resorts. The movie theatres segment operates multiscreen motion picture theatres in Wisconsin, Illinois, Iowa, Minnesota, Missouri, Nebraska, North Dakota, Ohio and others, a family entertainment center in Wisconsin and a retail center in Missouri; Hotels and Resorts segment owns and operates full-service hotels and resorts in Wisconsin, Illinois, and Nebraska and manages full-service hotels, resorts and other properties in Wisconsin, Minnesota, Texas, Nevada, California, and North Carolina. It generates maximum revenue from the Theatres segment.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.